Myriad Genetics Inc (NASDAQ:MYGN)
| 27.33 BATS BZX Real-Time Price As of 2:26pm ET |  -0.83 / -2.95%Today’s Change | 10.54 Today|||52-Week Range 33.97 | +38.20% Year-to-Date |
Latest MYGN News | Press Releases
| 3 Women Healthcare Stocks With Solid Growth Potential Amid COVID-19 Apr 09 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 28.16 |
| Today’s open | 28.72 |
| Day’s range | 27.26 - 28.72 |
| Volume | 10,829 |
| Average volume (3 months) | 829,604 |
| Market cap | $2.1B |
Data as of 2:26pm ET, 04/12/2021
Growth & Valuation
| Earnings growth (last year) | -4,389.30% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +6.00% |
| Revenue growth (last year) | -24.97% |
| P/E ratio | NM |
| Price/Sales | 1.32 |
| Price/Book | 2.29 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| LNTHLantheus Holdings In... | +0.09 | +0.43% |
| VIVOMeridian Bioscience ... | -1.02 | -4.08% |
| TRILTrillium Therapeutic... | -0.62 | -5.94% |
| CLDXCelldex Therapeutics... | -0.12 | -0.58% |
Data as of 2:25pm ET, 04/12/2021
Financials
| Next reporting date | November 9, 2021 |
| EPS forecast (this quarter) | -$0.16 |
| Annual revenue (last year) | $638.6M |
| Annual profit (last year) | -$199.5M |
| Net profit margin | -31.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Salt Lake City, Utah |
Forecasts
